Healthcare
94 articles in this category (Page 2 of 4)
ImmunityBio (IBRX): 5-Day Bullish Outlook Driven by EU ANKTIVA Approval Amidst Cash Burn Risks
ImmunityBio's recent EU marketing authorization for ANKTIVA provides a strong short-term bullish catalyst, though extreme negative margins cap long-term confidence.
BillionToOne (BLLN): Medicare Coverage and Upcoming Earnings Setup Potential Rebound
Recent Medicare coverage for Northstar Select and reiterated revenue guidance provide strong catalysts for BLLN ahead of its March 4 earnings, despite weak technical momentum.
Novo Nordisk Faces Severe Headwinds Following CagriSema Trial Failure: 5-Day Bearish Outlook
Novo Nordisk's stock faces continued downward pressure after its weight-loss drug CagriSema missed trial goals against Eli Lilly, prompting a severe 2026 guidance cut.
EU Approval Fuels Rally, But Profits Remain Distant: A 21-Day Outlook for ImmunityBio
Quantitative analysis of ImmunityBio (IBRX) following a strict 12-step methodology, focusing on the impact of the EU approval for Anktiva and upcoming earnings within a 21-day horizon.
MASI Technical Overbought Condition and Lack of Catalyst Suggest Sideways Trading
Quantitative analysis of Masimo Corporation (MASI) stock price direction over the specified horizon, based on provided financial data and structured news, following a strict 12-step methodological protocol.
Oversold IRON Awaits Earnings Catalyst; Sideways Drift Likely Until Then
Quantitative analysis of Disc Medicine (IRON) integrating recent neutral news, oversold technicals, high volatility profile, and a lack of immediate, specific price catalysts ahead of earnings.
Artera Enhances Prostate Cancer Diagnostics with AWS
Artera's AI-powered prostate cancer test, built on Amazon Web Services (AWS), accelerates time to results and enables personalized treatment recommendations, with the FDA granting De Novo authorization for the ArteraAI Prostate platform.